CureVac Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de CureVac de 35.8% y 31.9% por año respectivamente. Se prevé que el BPA crezca en un 34.6% al año. Se espera que la rentabilidad financiera sea de -78.9% en 3 años.

Información clave

50.5%

Tasa de crecimiento de los beneficios

47.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.7%
Tasa de crecimiento de los ingresos	32.2%
Rentabilidad financiera futura	-85.3%
Cobertura de analistas	Good
Última actualización	01 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

Recent updates

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

CureVac, Bayer agree to COVID-19 vaccine alliance - report

Jan 07

Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?

Dec 23

Curevac advances COVID-19 vaccine candidate to Phase 3 trial

Dec 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:CVAC - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	124	-80	-64	-21	6
12/31/2025	79	-129	-147	-105	7
12/31/2024	58	-184	-227	-227	7
12/31/2023	54	-260	-323	-268	N/A
9/30/2023	43	-302	-335	-273	N/A
6/30/2023	38	-301	-325	-249	N/A
3/31/2023	50	-291	-338	-249	N/A
12/31/2022	67	-249	-379	-286	N/A
9/30/2022	97	-122	-527	-420	N/A
6/30/2022	115	-219	-758	-659	N/A
3/31/2022	117	-313	-782	-673	N/A
12/31/2021	103	-412	-861	-733	N/A
9/30/2021	68	-468	-228	-109	N/A
6/30/2021	44	-361	N/A	N/A	N/A
3/31/2021	56	-219	250	329	N/A
12/31/2020	49	-129	475	522	N/A
9/30/2020	50	-107	36	62	N/A
3/31/2020	17	-102	-82	-67	N/A
12/31/2019	17	-100	-99	-87	N/A
12/31/2018	13	-71	-89	-74	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CVAC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CVAC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CVAC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (31.9% al año) de CVAC crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (31.9% al año) de CVAC crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: CVAC se prevé que no sea rentable en 3 años.

CureVac Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus revenue estimates decrease by 29%, EPS upgraded

Consensus revenue estimates increase by 57%

Consensus revenue estimates decrease by 42%, EPS upgraded

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac: Wait For Concrete News Before Investing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021

CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV

Co-Founder notifies of intention to sell stock

CureVac N.V. Announces Results of the Second Interim Analysis of its International Pivotal Phase 2b/3 Study in Approximatively 40,000 Subjects